

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
65503-BSerial No.
09/825,682

JAN 21 2003

INFORMATION DISCLOSURE CITATION
BY APPLICANT

(Use several sheets if necessary)

Applicants

Elena Feinstein and Orna Mor

Filing Date

April 4, 2001

Group

1634

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
DRS	5 4 2 2 2 4 3	06/06/95	Jalkanen et al.			
	5 8 5 6 1 3 6	01/05/99	Au-Young			
	6 2 0 7 3 8 0	03/27/01	Billing-Medel et al.			
	6 3 3 5 1 7 0	01/01/02	Orntoft			
DRS	09 6 7 0 6 7 2	09/27/00	Feinstein and Mor			

RECEIVED

JAN 22 2003

TECH CENTER 1800/2800

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No
WO 0 1 2 2 8 6 4	04/05/01	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DRS	Ozen, "Bladder Cancer," <i>Curr. Opin. Oncol.</i> 10(3):273-278 (1998)
	Torti and Lum, "The Biology and Treatment of Superficial Bladder Cancer," <i>J. Clin. Oncol.</i> 2(5):505-531 (1984)
	Grossman, "New Methods for Detection of Bladder Cancer," <i>Semin. Urol. Oncol.</i> 16(1):17-22 (1998)
	Sarver et al. "Exploring Catalytic RNAs (Roibozymes) as Anti-HIV Agents," pp. 305-325 in <i>Gene Regulation and AIDS</i> by Papas, Portfolio Publishing Co. Woodlands, Texas (1990)
	Culver, "Site-Directed recombinant for repair of mutations in the human ADA gene," (Abstract) <i>Antisense DNA & RNA based therapeutics</i> , Coronado, California (1998)
	Lacombe et al., "Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy; correlation to clinical outcome," <i>J. Urol.</i> 153(3) Part 1:564-572 (1995)
	Herskowitz "Functional inactivation of genes by dominant negative mutations" <i>Nature</i> 329: 219-222 (1987)
DRS	Hudson and Herr, "Carcinoma <i>in situ</i> of the bladder," <i>J. Urol.</i> 153(3) Part 1:564-572 (1995)

EXAMINER

DATE CONSIDERED

6/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Elena Feinstein and Orna Mor
U.S. Serial No.: 09/825,682
Filed: April 4, 2001
Title: SEQUENCES CHARACTERISTIC OF
BLADDER CANCER
Exhibit A

PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 65503-B	Serial No. 09/825,680
INFORMATION DISCLOSURE CITATION BY APPLICANT (Use several sheets if necessary)		Applicants Elena Feinstein and Orna Mordehai	Filing Date April 4, 2001
		Group 1634	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
[Signature]	Rosenthal et al., "Human bladder tumour cDNA library derived EST 15", Geneseq032802 Accession No. AAZ24403, submitted February 2000		
	National Institutes of Health, Mammalian Gene Collection, "Homo sapiens cDNA clone", EST Accession No. BG291376, submitted February 2000		
	Quark Biotech Inc., "Bladder cancer-associated sequence, TCC75E3", Geneseq032802 Accession No. AAS01308, submitted July 2001		
	Quark Biotech Inc., "Bladder cancer-associated sequence, TCC94G3", Geneseq032802 Accession No. AAS01297, submitted July 2001		
[Signature]	Billing-Medel et al., "Sequence 7 from patent US 6207380", GeneEmbl Accession No. AR139477, submitted June 2001		
EXAMINER: [Signature] DATE CONSIDERED: 6/9/03			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			